We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Low Blood Glucose Level in Diabetics Tied to Hospital Readmission

By LabMedica International staff writers
Posted on 23 May 2019
Print article
Image: Research shows that low blood glucose levels in diabetics are tied to hospital readmission (Photo courtesy of Maria Muccioli PhD).
Image: Research shows that low blood glucose levels in diabetics are tied to hospital readmission (Photo courtesy of Maria Muccioli PhD).
More than 29 million Americans are living with diabetes and an additional 86 million are at risk for developing the disease, In hospitalized patients, low blood sugar, also known as hypoglycemia, is associated with increased short- and long-term mortality risk.

One complication of diabetes, hypoglycemia, occurs most often in people taking medications to manage their blood sugar. These treatments can raise insulin levels too high, which can in turn cause blood glucose levels to drop too low. Hypoglycemia can be dangerous and, depending on the severity, can lead to various symptoms, including dizziness, confusion, anxiety, seizure or loss of consciousness.

Endocrinologists and their colleagues at the Baltimore Veterans Affairs Medical Center (Baltimore, MD, USA) investigated whether patients with diabetes and low glucose values during the last day of hospitalization are at increased risk of readmission or mortality. The evaluated readmission and death rates of more than 843,000 patients and found that low blood glucose levels were also associated with higher combined rates of 30-day readmission and mortality, and higher 30-, 90- and 180-day post-discharge mortality rates.

The investigators found that the rate ratios (RR) increased progressively for all five outcomes of interest (30-day readmission rate; 30-day, 90-day, and 180-day mortality rate; and combined 30-day readmission/mortality rate) as the minimum glucose concentrations progressively decreased below 90 to 99 mg/dL versus 100 to 109 mg/dL (30-day readmission RR, 1.01 to 1.45; 30-day readmission/mortality RR, 1.01 to 1.71; 30-day mortality RR, 0.99 to 5.82; 90-day mortality RR, 1.01 to 2.40; and 180-day mortality RR, 1.03 to 1.91). The 30-day readmission rate; 30-, 90-, and 180-day post-discharge mortality rate; and combined 30-day readmission/mortality rate were all greater for patients with diabetes with glucose levels <92.9 mg/dL; <45.2 mg/dL, 65.8 mg/dL, and 67.3 mg/dL; and <87.2 mg/dL, respectively.

The authors concluded that patients with diabetes who had hypoglycemia or near normal glucose values during the last day of hospitalization had higher rates of 30-day readmission and post discharge mortality. The study was published on May 1, 2019, in the Journal of Clinical Endocrinology & Metabolism.

Related Links:
Baltimore Veterans Affairs Medical Center

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.